摘要
目的探讨治疗前血清神经元特异性烯醇化酶（NSE）水平在预测晚期非小细胞肺癌（NSCLC）发生脑转移和患者预后的价值。方法回顾性分析128例晚期NSCLC患者的临床病理特征和治疗前血清NSE、癌胚抗原（CEA）、细胞角蛋白21-1片段（cyfra 21-1）、白蛋白（ALB）、白细胞（WBC）水平与NSCLC患者发生脑转移及其预后的关系。结果128例晚期NSCLC患者中，肺腺癌90例，肺鳞癌30例，大细胞未分化癌8例。血清NSE、CEA和cyfra 21—1的中位水平分别为13．6、7．8和6．1ng／ml，ALB和WBC水平分别为（35．41±5．60）g／L和（8．16±2．53）×10^9/ml。多因素Logistic分析结果显示，NSE水平与NSCLC患者脑转移有关（P=0．030）。28例脑转移患者和98例无脑转移患者治疗前NSE水平分别为（34．18±28．48）ng／ml和（13．87±4．49）ng／ml，差异有统计学意义（P〈0．05）。治疗前NSE水平升高组和NSE水平正常组患者的中位生存时间分别为3．5个月和10．7个月，差异有统计学意义（P〈0．05）。结论治疗前血清NSE水平与NSCLC患者脑转移和预后有关，可作为晚期NSCLC脑转移的预测因素，治疗前血清NSE高水平提示NSCLC患者预后较差。
Objective To explore the value of serum neuron-specific enolase （NSE） before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer （NSCLC）. Methods A total of 128 hospitalized patients with advanced NSCLC from Jan 2012 to Mar 2012 were followed up, and their elinicopathological data, serum NSE, carcinoembryonic antigen, cytokeratin 21-1 （cyfra21-1） levels, albumin （ALB）, white blood cell （WBC） before treatment were analyzed retrospectively to determine the factors affecting brain metastasis and prognosis of advanced NSCLC. Results Among the 128 NSCLC patients, 90 cases were of adenocarcinoma, 30 cases were of squamous cell carcinoma, and 8 cases were of large cell carcinoma. The median levels of pre-treatment NSE, CEA and cyfra21-1 were 13.6 ng/ml, 7.8 ng/ml and 6.1 ng/ml, respectively. The average levels of ALB and WBC were（35.41±5.60） g/L and （8.16±2.53） × 10^9/ml, respectively. Muhi-variate logistic regression analysis showed that serum NSE before treatment was associated with brain metastasis of advanced NSCLC （P = 0.030）. Pre-treatment NSE levels were （34.18±28.48） ng/ml in 28 patients with brain metastasis and （13.87±4.49） ng,/ml in 98 patients without brain metastasis （P〈0.05）. The median survival time were 3.5 months in patients with normal levels of NSE, and 10.7 months in patients with elevated levels of NSE pretreatment（ P〈 0.05 ）. Conclusions A higher pre-treatment level of NSE is closely correlated with brain metastasis of advanced NSCLC, and can be used as a predictor of brain metastases in advanced NSCLC. High pre-treatment levels of NSE indicate a poor prognosis in advanced NSCLC patients.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2015年第7期508-511,共4页
Chinese Journal of Oncology
基金
国家临床重点专科建设项目
关键词
癌
非小细胞肺
肿瘤转移
脑
预后
神经元特异性烯醇化酶
Carcinoma, non-small-cell lung
Neoplasm metastasis
Brain
Prognosis
Neuron-specific enolase
